Last reviewed · How we verify
NCT07145697
The Electroencephalographic Mechanisms of Anesthesia and Human Consciousness
Phase 4 trial testing Dexmedetomidine in Consciousness, Level Altered in 30 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Guangzhou General Hospital of Guangzhou Military Command |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 30 |
| Start date | 10 April 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 30 June 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Dexmedetomidine (dexmedetomidine) — full drug profile →
Conditions studied
- Consciousness, Level Altered — all drugs for Consciousness, Level Altered →
Sponsor
Guangzhou General Hospital of Guangzhou Military Command
Who can join
Adults 3 to 65, any sex, with Consciousness, Level Altered. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In the field of general anesthesia research, the neural mechanism underlying the loss of consciousness has long been a highly core issue. It remains unclear what consciousness is and how it emerges from brain activity. By studying anesthesia and sleep, the investigators aim to reveal what happens in the brain when consciousness is lost and when it returns. Dexmedetomidine, a widely used drug in clinical anesthetic practice, plays an important role in the anesthetic process due to its unique pharmacological properties. It hardly causes respiratory depression during the sedative and hypnotic process, which makes it occupy an important position in clinical anesthetic regimens. The emergence of stereoelectroencephalography (SEEG) technology has brought new opportunities for research on anesthesia mechanisms. Compared with traditional electroencephalographic (EEG), SEEG can directly penetrate into deep brain structures to record electrical activities, enabling precise localization of brain regions closely related to consciousness regulation. At present, although there have been some studies on the effects of dexmedetomidine on EEG activities, there are still many deficiencies. Most studies have focused on simple spectral analysis of EEG signals or observations of limited brain regions, lacking comprehensive multi-dimensional research on functional connectivity between brain regions, microstates, and complexity. Through monitoring key brain regions, the SEEG technology can obtain more targeted and accurate information, thereby providing strong support for comprehensively revealing the neural mechanisms of dexmedetomidine-induced loss of consciousness.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07145697
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Dexmedetomidine
Trials testing the same drug.
- NCT06824077 — Reducing Days DELirious With DEXmedetomidine as Part of an Intensive Care Unit Sleep Promotion Bundle · EARLY_PHASE1 · not yet recruiting
- NCT07398066 — DEXmedetomidine for Postoperative Analgesia and Delirium Prevention After NEUROsurgery (DEX-NEURO Trial) · NA · not yet recruiting
- NCT07377981 — An Exploratory Study of the Efficacy and Safety of Esketamine and Dexmedetomidine in Non-Intubated ICU Patients With Hyp · Phase 4 · not yet recruiting
- NCT07306702 — Dexmedetomidine-Enhanced PCIA After Lobectomy in Nicotine-Dependent Patients · Phase 4 · withdrawn
- NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting
Other recruiting trials for Consciousness, Level Altered
Currently open trials in the same condition.
- NCT03814356 — Stimulant Therapy Targeted to Individualized Connectivity Maps to Promote ReACTivation of Consciousness · Phase 1 · active not recruiting
Other Guangzhou General Hospital of Guangzhou Military Command trials
Trials by the same sponsor.
- NCT07462949 — A Study on Median Effective Concentration of Ciprofol Combined With Remifentanil Via Target-controlled Infusion for Inhi · NA · completed
- NCT05187455 — Pharmacokinetics of Sugammadex for the Reversal of Moderate Neuromuscular Blockade in Patients During Renal Transplantat · Phase 4 · unknown
- NCT05202899 — Effect of Sugammadex for Reversal of Rocuronium-induced Neuromuscular Block on Perioperative Management of Awake Craniot · Phase 4 · unknown
- NCT04794673 — Cortex Motor Function Reorganization in Stroke Patients · completed
- NCT05328778 — Pharmacokinetics of Sugammadex in Reversal of Vecuronium-induced Neuromuscular Blockade in Patients During Laparoscopic · Phase 4 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07145697 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangzhou General Hospital of Guangzhou Military Command
- Last refreshed: 28 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07145697.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing